PEDIATRICS Vol. 47 No. 5 May 1971, pp. 807-810
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thaler, M. M.
Right arrow Articles by Schmid, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thaler, M. M.
Right arrow Articles by Schmid, R.

DRUGS AND BILIRUBIN

M. Michael Thaler M.D.1 and Rudi Schmid M.D.1

1 Departments of Pediatrics and Medicine, University of California, San Francisco, California 94122

Current concepts of the mechanisms of biotransformation and drug detoxification evolved largely as a result of studies of the last decade and a half.1 It was demonstrated that most of the enzyme systems responsible for the oxidative, reductive, hydrolytic, and conjugating reactions of drugs, toxins, and many endogenous substances are located in the endoplasmic reticulum of the liver cell, operationally defined as the microsomal fraction. Remmer2 and Conney and his collaborators3 were among the first to point out that many of the compounds metabolized by these pathways have the capacity of enhancing not only their own metabolic transformation, but also that of substances chemically or biologically unrelated to the stimulating agent.